Last reviewed · How we verify
Xingnaojing injection + Shuxuetong oral liquid
Xingnaojing injection + Shuxuetong oral liquid is a Traditional Chinese medicine combination / Herbal extract Small molecule drug developed by Peking University Third Hospital. It is currently FDA-approved for Acute ischemic stroke, Cerebral infarction, Transient ischemic attack.
This combination therapy improves cerebral blood flow and reduces blood viscosity to enhance microcirculation and oxygen delivery to brain tissue.
This combination therapy improves cerebral blood flow and reduces blood viscosity to enhance microcirculation and oxygen delivery to brain tissue. Used for Acute ischemic stroke, Cerebral infarction, Transient ischemic attack.
At a glance
| Generic name | Xingnaojing injection + Shuxuetong oral liquid |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | Traditional Chinese medicine combination / Herbal extract |
| Modality | Small molecule |
| Therapeutic area | Neurology / Cerebrovascular disease |
| Phase | FDA-approved |
Mechanism of action
Xingnaojing injection is a traditional Chinese medicine derivative that promotes blood circulation and removes blood stasis, while Shuxuetong oral liquid (derived from Lumbricus) further reduces blood viscosity and improves rheological properties. Together, they work to enhance cerebral perfusion and metabolic function in acute ischemic stroke and related cerebrovascular conditions.
Approved indications
- Acute ischemic stroke
- Cerebral infarction
- Transient ischemic attack
Common side effects
- Gastrointestinal upset
- Dizziness
- Headache
- Allergic reaction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xingnaojing injection + Shuxuetong oral liquid CI brief — competitive landscape report
- Xingnaojing injection + Shuxuetong oral liquid updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI
Frequently asked questions about Xingnaojing injection + Shuxuetong oral liquid
What is Xingnaojing injection + Shuxuetong oral liquid?
How does Xingnaojing injection + Shuxuetong oral liquid work?
What is Xingnaojing injection + Shuxuetong oral liquid used for?
Who makes Xingnaojing injection + Shuxuetong oral liquid?
What drug class is Xingnaojing injection + Shuxuetong oral liquid in?
What development phase is Xingnaojing injection + Shuxuetong oral liquid in?
What are the side effects of Xingnaojing injection + Shuxuetong oral liquid?
Related
- Drug class: All Traditional Chinese medicine combination / Herbal extract drugs
- Manufacturer: Peking University Third Hospital — full pipeline
- Therapeutic area: All drugs in Neurology / Cerebrovascular disease
- Indication: Drugs for Acute ischemic stroke
- Indication: Drugs for Cerebral infarction
- Indication: Drugs for Transient ischemic attack
- Compare: Xingnaojing injection + Shuxuetong oral liquid vs similar drugs
- Pricing: Xingnaojing injection + Shuxuetong oral liquid cost, discount & access